Maxim Group Maintains Buy on Zevra Therapeutics, Raises Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
Maxim Group analyst Jason McCarthy maintains a Buy rating on Zevra Therapeutics and raises the price target from $18 to $25.
September 24, 2024 | 1:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Maxim Group analyst Jason McCarthy has reiterated a Buy rating for Zevra Therapeutics and increased the price target from $18 to $25, indicating a positive outlook for the stock.
The increase in the price target from $18 to $25 by a reputable analyst suggests a strong positive outlook for Zevra Therapeutics. This is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100